Combination Treatment May Improve Multiple Myeloma Outcomes
STOCKHOLM — Patients with relapsed or refractory multiple myeloma (RRMM) benefit from teclistamab plus daratumumab (Tec-Dara), irrespective of cytogenetic and functional risk status, according to research presented at the European Hematology Association ( …